The global nanomedicine market size was accounted for USD 209.43 billion in 2024, grew to USD 233.70 billion in 2025 and is predicted to surpass around USD 627.03 billion by 2034, representing a healthy CAGR of 11.59% between 2025 and 2034. The North America nanomedicine market size was calculated at USD 105.89 billion in 2024 and is expected to grow at a fastest CAGR of 11.60% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Nanomedicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Nanomedicine Market, by Modality Type, 2025-2034
8.1.1. Treatments
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Diagnostics
8.1.2.1. Market Revenue and Forecast (2022-2034)
9.1. Nanomedicine Market, by Application, 2025-2034
9.1.1. Drug Delivery
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Diagnostic Imaging
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2022-2034)
9.1.4. Regenerative Medicine
9.1.4.1. Market Revenue and Forecast (2022-2034)
9.1.5. Implants
9.1.5.1. Market Revenue and Forecast (2022-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2022-2034)
10.1. Nanomedicine Market, by Indication Type, 2025-2034
10.1.1. Oncological Diseases
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast (2022-2034)
10.1.4. Orthopedic Diseases
10.1.4.1. Market Revenue and Forecast (2022-2034)
10.1.5. Neurological Diseases
10.1.5.1. Market Revenue and Forecast (2022-2034)
10.1.6. Urological Diseases
10.1.6.1. Market Revenue and Forecast (2022-2034)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2022-2034)
11.1. Nanomedicine Market, by Nanomolecule Type, 2025-2034
11.1.1. Nanoparticles
11.1.1.1. Market Revenue and Forecast (2022-2034)
11.1.2. Nanoshells
11.1.2.1. Market Revenue and Forecast (2022-2034)
11.1.3. Nanotubes
11.1.3.1. Market Revenue and Forecast (2022-2034)
11.1.4. Nanodevices
11.1.4.1. Market Revenue and Forecast (2022-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Modality (2022-2034)
12.1.2. Market Revenue and Forecast, by Application (2022-2034)
12.1.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.1.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.1.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.1.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.1.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Modality (2022-2034)
12.1.6.2. Market Revenue and Forecast, by Application (2022-2034)
12.1.6.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.1.6.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Modality (2022-2034)
12.2.2. Market Revenue and Forecast, by Application (2022-2034)
12.2.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.2.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.2.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.2.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.2.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Modality (2022-2034)
12.2.6.2. Market Revenue and Forecast, by Application (2022-2034)
12.2.6.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.2.6.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Modality (2022-2034)
12.2.7.2. Market Revenue and Forecast, by Application (2022-2034)
12.2.7.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.2.7.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Modality (2022-2034)
12.2.8.2. Market Revenue and Forecast, by Application (2022-2034)
12.2.8.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.2.8.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Modality (2022-2034)
12.3.2. Market Revenue and Forecast, by Application (2022-2034)
12.3.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.3.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.3.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.3.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.3.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Modality (2022-2034)
12.3.6.2. Market Revenue and Forecast, by Application (2022-2034)
12.3.6.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.3.6.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Modality (2022-2034)
12.3.7.2. Market Revenue and Forecast, by Application (2022-2034)
12.3.7.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.3.7.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Modality (2022-2034)
12.3.8.2. Market Revenue and Forecast, by Application (2022-2034)
12.3.8.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.3.8.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Modality (2022-2034)
12.4.2. Market Revenue and Forecast, by Application (2022-2034)
12.4.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.4.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.4.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.4.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.4.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Modality (2022-2034)
12.4.6.2. Market Revenue and Forecast, by Application (2022-2034)
12.4.6.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.4.6.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Modality (2022-2034)
12.4.7.2. Market Revenue and Forecast, by Application (2022-2034)
12.4.7.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.4.7.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Modality (2022-2034)
12.4.8.2. Market Revenue and Forecast, by Application (2022-2034)
12.4.8.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.4.8.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Modality (2022-2034)
12.5.5.2. Market Revenue and Forecast, by Application (2022-2034)
12.5.5.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.5.5.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Modality (2022-2034)
12.5.6.2. Market Revenue and Forecast, by Application (2022-2034)
12.5.6.3. Market Revenue and Forecast, by Indication Type (2022-2034)
12.5.6.4. Market Revenue and Forecast, by Nanomolecule Type (2022-2034)
13.1. Sanofi SA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Abbott
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CombiMatrix Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Celgene Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Johnson & Johnson Services Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Luminex Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck & Company Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Nanosphere Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample